MindWalk Holdings Corp.

MindWalk Holdings Corp. is an AI-driven biopharmaceutical discovery and development company focused on creating safer and more efficacious novel therapeutic antibodies. The company operates in the pharmaceutical and biotechnology industries, which are characterized by rapid and continuous technological innovation. The industry follows an outsourcing trend in non-clinical discovery stages of drug discovery, with pharmaceutical and biotechnology companies generally increasing their outsourcing of non-clinical research support activities such as antibody discovery over the past decade.

The company competes with pharmaceutical companies, biotechnology companies, contract research companies, academic institutions, governmental agencies, and other research organizations worldwide. Many competitors offer a broader range of products and services and have greater access to financial, technical, scientific, business development, recruiting, and other resources. Some competitors may also operate with a lower cost structure. The company believes there are only a limited number of full-service, biologics, CRO firms.

MindWalk generates revenue primarily through project-based CRO and related services, with revenues remaining primarily derived from project-based CRO and related services. The company also aims to generate revenue from subscriptions, partnerships, licenses, milestone payments, royalty payments, and other commercial arrangements. The company does not seek regulatory approval of its early-stage candidates itself, but instead aims to out-license its assets prior to clinical trial research. Customer segments include small and larger pharma entities, biotechnology companies, academic institutions, government laboratories, and private foundations.

The company's operations include BioStrand operations, AI-driven software development, internal discovery efforts, and proprietary technology platforms. The company's proprietary AI platforms include the LensAI platform and HYFT technology. The company also offers services such as Rapid Prime, B cell Select, DeepDisplay, and methods for the production of complex proteins and antibodies. The company has had several assets enter the clinical successfully.

The company has ongoing internal discovery and therapeutic programs, including AI-powered pipeline initiatives and recent announcements relating to dengue, GLP-1 and longevity-related research. The company is making a strategic shift to increase the number of larger pharma and biotech clients, including the size of each service contract. The company is currently investing in brand awareness through a rebranding project due to commence in the second quarter of fiscal year 2026. The company has deployed a sales team tasked with continually sourcing and providing market intelligence.

The company has historically incurred net losses and has incurred operating losses in every reporting period since inception, with a significant accumulated deficit. Operating costs are expected to increase in the near term as the company continues to build its AI-driven software development, namely LensAI. The company has negative cash flow from operating activities. There is no assurance that sufficient revenues will be generated in the near future.

The company expects that operating costs will increase in the near term as it continues to build its AI-driven software development, namely LensAI, and expects that this will continue until either subscription-based payments of future product sales, partnership fees, licensing fees, milestone payments or royalty payments are sufficient to generate revenues to fund continuing operations.

The company's strategic plans increasingly depend on its ability to develop, commercialize and scale its AI-driven software offerings, including LensAI, while continuing to generate sufficient revenue from subscriptions, partnerships, licenses, milestone payments and other commercial arrangements. The company's future growth may depend in part on the willingness of current and prospective clients to adopt AI-based, software-enabled and, over time, SaaS-based tools as part of their drug discovery and development workflows. The company continues to invest in research and development across its business, including BioStrand operations, AI-driven software development, internal discovery efforts and proprietary technology platforms.

The company's shift toward a more software-led model, while continuing to operate wet lab services, may disrupt operations, service quality and client relationships. The company currently operates a business that combines in silico technologies with wet lab infrastructure and client-facing laboratory services. The company must manage the transition carefully while maintaining service levels, turnaround times, quality standards and client satisfaction across its wet lab operations.

The company's research and development activities are inherently uncertain and may not result in commercially viable technologies, products, services or internal programs. Research and development remains a cornerstone of the company's strategy, but such activities may not result in the successful development of new and innovative processes, procedures, approaches to antibody production, software tools or new therapeutic assets.

The company's internal programs and pipeline assets may not advance as planned or achieve commercial success. The company does not seek regulatory approval of its early-stage candidates itself and instead aims to out-license assets prior to clinical trial research, which means the advancement and commercial potential of internal programs may depend substantially on the company's ability to secure and maintain favorable collaborations, licenses or other strategic arrangements.

The company may need to raise additional funds through issuances of Common Shares or through loan financing. There is no assurance that additional capital or other types of financing will be available if needed or that these financings will be on terms at least as favorable as those previously obtained, or at all. The company may sell additional equity securities in subsequent offerings and may issue additional equity securities to finance operations, acquisitions or other projects.

Global economic instability and geopolitical tensions, including the imposition of tariffs and other trade barriers, could have an adverse effect on the company's business and results of operations. Market disruptions have included extreme volatility in securities prices, as well as severely diminished liquidity and credit availability. Trade barriers or tariffs may be imposed on a temporary or permanent basis, which could decrease the company's ability to source, produce and distribute its products or obtain financing.

The company is subject to evolving laws, regulations and expectations relating to data privacy, data security and the use of artificial intelligence. The company is required to comply with data privacy and security laws in multiple jurisdictions, including the GDPR and the CCPA. As the company's business increasingly incorporates AI-enabled tools and data-driven technologies, it may become subject to new or changing laws, regulations, industry standards, contractual requirements and governmental expectations relating to the development, deployment, transparency, security, accountability and permitted uses of AI.

The company currently has negative operating cash flows and has historically incurred net losses, with no assurance that sufficient revenues will be generated in the near future. The company does not have sufficient cash reserves to fund its operations for the next twelve months, which raises substantial doubt about its ability to continue as a going concern. The company may fail to remediate a material weakness in internal control over financial reporting, as management concluded that the company did not have sufficient resources to assist in identifying, evaluating and addressing complex technical accounting issues on a timely basis. The company's shift toward a more software-led model may disrupt operations, service quality and client relationships, and the market may adopt AI-based and SaaS-based tools more slowly than expected. The company's internal programs and pipeline assets, including those relating to dengue, GLP-1 and longevity, may not advance as planned or achieve commercial success, and the company depends on its ability to secure and maintain favorable collaborations, licenses or other strategic arrangements.

Management's message emphasizes the company's strategic shift toward a more software-led model, with a focus on developing, commercializing and scaling AI-driven software offerings including LensAI, while continuing to operate wet lab services. Key strategic priorities include executing the software-led strategy, integrating in silico technologies with broader operations, and maintaining market awareness for offerings. Management acknowledges that operating costs are expected to increase in the near term as the company continues to build its AI-driven software development, and that there can be no assurance that these investments will generate the anticipated level of commercial adoption, recurring revenue or profitability within the expected timeframes or at all.